Michelle Dyer, APRN
Psychiatric/Mental Health · Lake Charles, LANPI 1790079465
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $20,160 of the $32,948 with a category attached, or 61.2%. Johnson & Johnson accounts for 73.8% of it on its own, with 26 other manufacturers making up the rest. 2025 is the largest year on record at $17,296, more than ten times the $1,588 reported in 2021. Among psychiatric/mental health clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 596 payments — averaging $55.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$24K
- AbbVie$2K
- Otsuka America Pharmaceutical, Inc.$1K
- Neurocrine Biosciences, Inc.$909
- Alkermes, Inc.$792
- Vanda Pharmaceuticals Inc.$621
- plus $3K from 21 others
What the payments were for
- Speaking & faculty fees$20,16061%
- Travel & lodging$2,1737%
- Food & beverage$10,55632%
- Education$600%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 81 | $24,331 |
| AbbVie | 144 | $2,058 |
| Otsuka America Pharmaceutical, Inc. | 85 | $1,191 |
| Neurocrine Biosciences, Inc. | 33 | $909 |
| Alkermes, Inc. | 50 | $792 |
| Vanda Pharmaceuticals Inc. | 43 | $621 |
| Axsome Therapeutics, Inc. | 23 | $504 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 29 | $484 |
| Teva Pharmaceuticals USA, Inc. | 18 | $356 |
| Sunovion Pharmaceuticals Inc. | 25 | $313 |
| Idorsia Pharmaceuticals US Inc | 11 | $256 |
| Corium, LLC | 15 | $211 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $199 |
| AstraZeneca | 1 | $130 |
| GSK | 1 | $113 |
| Supernus Pharmaceuticals, Inc. | 6 | $102 |
| Collegium Pharmaceutical, Inc. | 5 | $100 |
| Ironshore Pharmaceuticals Inc. | 3 | $53 |
| Lundbeck LLC | 2 | $42 |
| Indivior Inc. | 2 | $39 |
| Merck | 2 | $34 |
| Bausch Health US, LLC | 2 | $30 |
| Noven Therapeutics, LLC | 1 | $22 |
| Neos Therapeutics, LP | 1 | $17 |
| Neuronetics, Inc. | 1 | $16 |
| Alfasigma USA, Inc. | 1 | $14 |
| Eisai Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPRAVATO$22,831
- INGREZZA$256
- QUVIVIQ$125
- TRELEGY ELLIPTA$113
- Auvelity$111
- ABILIFY MAINTENA$111
How this compares
$32,948 in reported general payments places this provider in the 95th percentile of 615 psychiatric/mental health providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 103 | $164,051 |
| IngrezzaValbenazine Tosylate | 18 | $150,120 |
| RexultiBrexpiprazole | 26 | $69,074 |
| FanaptIloperidone | 17 | $36,665 |
| TrintellixVortioxetine Hydrobromide | 40 | $23,155 |
| QuviviqDaridorexant Hcl | 21 | $10,094 |
| Jornay PmMethylphenidate Hcl | 18 | $8,073 |
| Lurasidone Hcl | 44 | $6,798 |
| BelsomraSuvorexant | 11 | $4,584 |
| Aripiprazole | 121 | $4,421 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 107 | $3,947 |
| Duloxetine Hcl | 116 | $3,646 |
| Divalproex Sodium ErDivalproex Sodium | 53 | $3,250 |
| Trazodone Hcl | 197 | $2,912 |
| Alprazolam ErAlprazolam | 40 | $2,544 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $2,058 | $164,051103 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $909 | $150,12018 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,191 | $69,07426 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $621 | $36,66517 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $199 | $23,15540 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $256 | $10,09421 claims |
| Ironshore Pharmaceuticals Inc.Jornay Pm | $53 | $8,07318 claims |
| MerckBelsomra | $34 | $4,58411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 615 psychiatric/mental health providers in Louisiana.
Other psychiatric/mental health in Lake Charles
- Sattaria DilksLake Charles$57K
- Erica HessiferLake Charles$13K
- Candyce BrownLake Charles$13K
- Bethanne CarsonLake Charles$12K
- Morgan UnserLake Charles$9K
- Eric RachalLake Charles$9K
- Lori KayLake Charles$9K
- Valarie ClarkLake Charles$8K
- Julie DyrekLake Charles$8K
- Halie OryLake Charles$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.